Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 ...
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...
Soligenix Inc ((SNGX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing ...
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
60 Degrees Pharmaceuticals, Inc. announced the approval of an Investigational Review Board (IRB) for a Phase II clinical study aimed at evaluating the efficacy and safety of tafenoquine, marketed as ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback